ANAB
AnaptysBio, Inc. NASDAQ Listed Jan 26, 2017$57.51
+1.30%
vs $56.77
Mkt Cap $1.8B
52w Low $12.93
78.4% of range
52w High $69.78
50d MA $57.19
200d MA $36.05
P/E (TTM)
—
EV/EBITDA
25.7x
P/B
43.0x
Debt/Equity
0.4x
ROE
-35.6%
P/FCF
91.9x
RSI (14)
54.90
ATR (14)
$2.77
Beta
0.41
50d MA
$57.19
200d MA
$36.05
Avg Volume
588.2K
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
10770 Wateridge Circle · San Diego, CA 92121-5801 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 12, 2026 | AMC | -0.64 | -1.84 | -185.9% | 65.58 | -0.7% | -4.4% | -0.8% | +1.5% | -7.0% | +1.8% | — |
| Mar 3, 2026 | AMC | 0.89 | 1.58 | +77.5% | 35.22 | +6.2% | +14.6% | -5.4% | -3.3% | +7.7% | +3.9% | — |
| Nov 4, 2025 | AMC | -1.06 | 0.52 | +149.1% | 23.16 | +12.9% | +3.6% | +6.1% | +3.8% | -14.3% | -1.2% | — |
| Aug 7, 2025 | AMC | -1.50 | -1.34 | +10.7% | 13.58 | +1.8% | +3.2% | -4.9% | +0.6% | +3.0% | -3.6% | — |
| May 5, 2025 | AMC | -1.30 | -1.28 | +1.5% | 13.82 | +2.2% | -3.0% | -2.2% | -0.5% | +0.1% | +2.2% | — |
| Feb 27, 2025 | AMC | -1.55 | -0.72 | +53.5% | 10.93 | +18.7% | +2.6% | -12.9% | +4.2% | +9.8% | -2.1% | — |
| Nov 5, 2024 | AMC | -1.72 | -1.14 | +33.7% | 13.25 | +11.8% | +11.8% | -3.2% | -0.8% | +5.1% | -4.0% | — |
| Aug 5, 2024 | AMC | -1.20 | -1.71 | -42.5% | 21.58 | +4.0% | -0.9% | -1.7% | +6.5% | -1.6% | +2.1% | — |
| May 9, 2024 | AMC | -1.54 | -1.64 | -6.5% | 17.49 | -0.3% | -10.7% | +2.4% | +5.3% | +1.4% | -0.5% | — |
| Mar 12, 2024 | AMC | -1.60 | -1.59 | +0.7% | 17.37 | -0.3% | -5.2% | -4.4% | -0.6% | -1.2% | +0.4% | — |
| Nov 2, 2023 | AMC | -1.72 | -1.41 | +18.0% | 10.80 | +8.9% | +8.2% | -5.0% | -0.9% | -6.2% | -3.8% | — |
| Aug 7, 2023 | AMC | -1.70 | -1.50 | +11.5% | 12.31 | +3.2% | +2.6% | -6.7% | +2.2% | +5.1% | +1.4% | — |
| May 11, 2023 | AMC | -1.04 | -1.58 | -51.9% | 13.84 | -0.1% | -6.3% | -0.5% | -3.8% | +2.3% | -0.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 10 | H.C. Wainwright | Reiterates | Buy | $95 | $51.63 | $50.99 | -1.2% | +0.9% | +4.1% | +3.4% | +6.1% | -3.2% |
| Apr 28 | Leerink Partners | Maintains | Outperform → Outperform | — | $66.59 | $67.16 | +0.9% | -0.7% | -5.7% | +5.4% | +1.6% | +4.5% |
| Apr 22 | Barclays | Maintains | Overweight → Overweight | — | $51.82 | $51.56 | -0.5% | +3.3% | -4.3% | +14.8% | +13.1% | -0.7% |
| Apr 21 | UBS | Maintains | Buy → Buy | — | $50.95 | $51.08 | +0.3% | +1.7% | +3.3% | -4.3% | +14.8% | +13.1% |
| Mar 31 | Piper Sandler | Maintains | Overweight → Overweight | — | $36.92 | $38.33 | +3.8% | +0.1% | +2.3% | +1.7% | +8.2% | -0.5% |
| Mar 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.26 | $38.03 | -0.6% | -3.5% | +0.1% | +2.3% | +1.7% | +8.2% |
| Mar 17 | UBS | Maintains | Buy → Buy | — | $43.19 | $43.37 | +0.4% | +3.9% | -3.8% | +0.0% | -3.6% | +0.6% |
| Mar 12 | Wedbush | Maintains | Outperform → Outperform | — | $43.11 | $43.12 | +0.0% | -1.3% | +1.6% | -0.0% | +3.9% | -3.8% |
| Mar 9 | Truist | Maintains | Hold → Hold | — | $36.94 | $36.88 | -0.2% | +7.7% | +3.9% | +4.3% | -1.3% | +1.6% |
| Mar 5 | Stifel | Maintains | Buy → Buy | — | $40.37 | $39.67 | -1.7% | -5.4% | -3.3% | +7.7% | +3.9% | +4.3% |
| Mar 4 | Barclays | Maintains | Overweight → Overweight | — | $35.22 | $37.39 | +6.2% | +14.6% | -5.4% | -3.3% | +7.7% | +3.9% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $35.22 | $37.39 | +6.2% | +14.6% | -5.4% | -3.3% | +7.7% | +3.9% |
| Jan 20 | Barclays | Maintains | Overweight → Overweight | — | $30.45 | $30.00 | -1.5% | +1.2% | +1.0% | +1.4% | +0.4% | -0.9% |
| Dec 17 | Barclays | Maintains | Overweight → Overweight | — | $30.02 | $29.65 | -1.2% | +1.5% | +4.0% | +3.3% | +2.5% | -0.6% |
| Dec 11 | Stifel | Maintains | Buy → Buy | — | $29.97 | $29.71 | -0.9% | +1.8% | -1.8% | +1.4% | -1.2% | +1.5% |
| Nov 24 | Wedbush | Maintains | Outperform → Outperform | — | $26.41 | $26.49 | +0.3% | +5.9% | -1.1% | +1.6% | -1.2% | -0.8% |
| Nov 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.41 | $26.49 | +0.3% | +5.9% | -1.1% | +1.6% | -1.2% | -0.8% |
| Nov 11 | Barclays | Maintains | Overweight → Overweight | — | $22.65 | $22.02 | -2.8% | -1.2% | -1.4% | +0.5% | +1.7% | +2.8% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.65 | $22.02 | -2.8% | -1.2% | -1.4% | +0.5% | +1.7% | +2.8% |
| Nov 10 | Truist | Maintains | Hold → Hold | — | $26.43 | $21.33 | -19.3% | -14.3% | -1.2% | -1.4% | +0.5% | +1.7% |
| Nov 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $23.16 | $26.15 | +12.9% | +3.6% | +6.1% | +3.8% | -14.3% | -1.2% |
| Nov 5 | Guggenheim | Maintains | Buy → Buy | — | $23.16 | $26.15 | +12.9% | +3.6% | +6.1% | +3.8% | -14.3% | -1.2% |
| Oct 29 | Stifel | Maintains | Buy → Buy | — | $24.11 | $25.27 | +4.8% | -0.1% | +1.0% | +0.3% | -1.5% | -3.6% |
| Oct 15 | Wedbush | Maintains | Outperform → Outperform | — | $21.23 | $21.03 | -0.9% | +7.7% | +0.3% | +0.7% | +1.9% | -3.3% |
| Sep 30 | Wedbush | Maintains | Outperform → Outperform | — | $15.51 | $17.11 | +10.3% | +31.6% | +4.4% | -2.0% | -1.2% | -2.2% |
| Sep 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.51 | $17.11 | +10.3% | +31.6% | +4.4% | -2.0% | -1.2% | -2.2% |
| Aug 12 | UBS | Maintains | Neutral → Neutral | — | $13.33 | $13.31 | -0.1% | +0.6% | +3.0% | -3.6% | +0.9% | -0.6% |
| Aug 7 | Wedbush | Maintains | Outperform → Outperform | — | $15.03 | $15.71 | +4.5% | -9.6% | +3.2% | -4.9% | +0.6% | +3.0% |
| Jul 24 | JP Morgan | Maintains | Overweight → Overweight | — | $18.00 | $18.77 | +4.3% | -0.1% | -0.2% | -1.3% | -1.4% | -4.7% |
| Jun 4 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $15.68 | $16.43 | +4.8% | -9.6% | -0.6% | +12.1% | -2.2% | +3.4% |
| May 28 | Guggenheim | Maintains | Buy → Buy | — | $13.42 | $14.09 | +5.0% | +3.8% | +8.0% | -1.5% | -1.7% | +7.6% |
| May 6 | Guggenheim | Maintains | Buy → Buy | — | $13.82 | $14.13 | +2.2% | -3.0% | -2.2% | -0.5% | +0.1% | +2.2% |
| May 1 | Wedbush | Maintains | Outperform → Outperform | — | $14.81 | $14.76 | -0.3% | -2.3% | -2.3% | -2.2% | -3.0% | -2.2% |
| Mar 5 | JP Morgan | Maintains | Overweight → Overweight | — | $10.17 | $10.23 | +0.6% | +9.8% | -2.1% | -0.4% | +2.4% | +4.8% |
| Mar 4 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $9.76 | $9.63 | -1.3% | +4.2% | +9.8% | -2.1% | -0.4% | +2.4% |
| Feb 13 | Wells Fargo | Maintains | Overweight → Overweight | — | $10.77 | $11.08 | +2.9% | +19.4% | +10.0% | -6.8% | -0.9% | -3.7% |
| Feb 12 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $8.25 | $8.37 | +1.5% | +30.5% | +19.4% | +10.0% | -6.8% | -0.9% |
| Feb 7 | Wedbush | Maintains | Outperform → Outperform | — | $10.72 | $10.73 | +0.1% | -9.3% | -10.8% | -4.8% | +30.5% | +19.4% |
| Feb 4 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $11.11 | $11.63 | +4.7% | -0.9% | -2.7% | +0.1% | -9.3% | -10.8% |
| Dec 19 | JP Morgan | Maintains | Overweight → Overweight | — | $10.23 | $10.10 | -1.3% | -2.2% | -3.0% | -4.0% | -0.5% | -1.1% |
| Dec 18 | Truist | Maintains | Hold → Hold | — | $10.66 | $10.97 | +2.9% | -4.0% | -2.2% | -3.0% | -4.0% | -0.5% |
| Dec 12 | Guggenheim | Maintains | Buy → Buy | — | $10.34 | $10.39 | +0.5% | -3.2% | +3.8% | +6.8% | -4.0% | -4.0% |
| Dec 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $10.34 | $10.39 | +0.5% | -3.2% | +3.8% | +6.8% | -4.0% | -4.0% |
| Dec 11 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $15.39 | $9.55 | -37.9% | -32.8% | -3.2% | +3.8% | +6.8% | -4.0% |
| Dec 2 | BTIG | Downgrade | Buy → Neutral | — | $16.64 | $15.68 | -5.8% | -2.3% | -9.7% | +9.4% | -1.7% | +4.9% |
| Nov 12 | JP Morgan | Maintains | Overweight → Overweight | — | $14.93 | $14.57 | -2.4% | -4.0% | -3.5% | -2.7% | -5.8% | -0.6% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.25 | $14.81 | +11.8% | +11.8% | -3.2% | -0.8% | +5.1% | -4.0% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.79 | $14.71 | -0.5% | -2.5% | +0.2% | -8.0% | -0.3% | +11.8% |
| Oct 30 | UBS | Maintains | Neutral → Neutral | — | $20.53 | $15.33 | -25.3% | -28.0% | -2.5% | +0.2% | -8.0% | -0.3% |
| Oct 21 | Guggenheim | Maintains | Buy → Buy | — | $23.32 | $23.80 | +2.1% | +1.1% | -0.6% | -1.1% | -7.3% | -0.6% |
No insider trades available.
8-K
AnaptysBio, Inc. -- 8-K Filing
AnaptysBio's pro forma financials indicate a significant corporate transaction occurred, likely an acquisition or merger, requiring investors to review the combined entity's projected balance sheet and operations through December 31, 2025.
Apr 24
8-K
AnaptysBio, Inc. -- 8-K Filing
AnaptysBio completed a spin-off creating First Tracks Biotherapeutics, with detailed agreements governing asset transfers, liability assumptions, and ongoing relationships between the two independent entities.
Apr 20
8-K · 7.01
! Medium
AnaptysBio, Inc. -- 8-K 7.01: Regulation FD Disclosure
AnaptysBio disclosed an investor presentation without material updates, suggesting the company is maintaining consistent messaging with stakeholders on its pipeline and strategic direction.
Mar 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 2,069,124 | $100M | Reduced | Dec 2025 |
| 2 | Tang Capital Management Llc | 1,332,087 | $65M | — | Dec 2025 |
| 3 | Vanguard Capital Management Llc | 853,151 | $47M | New | Mar 2026 |
| 4 | D.e. Shaw & Co | 579,296 | $32M | Reduced | Mar 2026 |
| 5 | Vanguard Portfolio Management Llc | 519,870 | $29M | New | Mar 2026 |
| 6 | Bank Of America Corp /de/ | 501,086 | $28M | Added | Mar 2026 |
| 7 | Arrowstreet Capital, Limited Partnership | 492,120 | $27M | Reduced | Mar 2026 |
| 8 | Millennium Management | 475,572 | $26M | Reduced | Mar 2026 |
| 9 | Fmr Llc | 472,704 | $26M | Added | Mar 2026 |
| 10 | Two Sigma Investments, Lp | 465,083 | $26M | Added | Mar 2026 |
| 11 | Woodline Partners Lp | 344,256 | $19M | Reduced | Mar 2026 |
| 12 | Synergy Asset Management, Llc | 317,106 | $18M | New | Mar 2026 |
| 13 | Nuveen, Llc | 316,065 | $18M | — | Mar 2026 |
| 14 | Qube Research & Technologies Ltd | 254,736 | $14M | Added | Mar 2026 |
| 15 | Citadel Advisors Llc | 233,450 | $13M | Added | Mar 2026 |
| 16 | Northern Trust Corp | 183,519 | $10M | Added | Mar 2026 |
| 17 | Ensign Peak Advisors, Inc | 125,633 | $7M | Reduced | Mar 2026 |
| 18 | Invesco Ltd. | 121,103 | $7M | Reduced | Mar 2026 |
| 19 | Victory Capital Management Inc | 108,203 | $6M | Reduced | Mar 2026 |
| 20 | Connor, Clark & Lunn Investment Management Ltd. | 122,476 | $6M | New | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.80B
Enterprise Value
$1.50B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.75x
P/B
42.95x
P/S
7.76x
P/FCF
91.92x
EV/EBITDA
25.70x
Shares Out
31.3M
Financials (TTM)
Revenue
$232.4M
Net Income
-$26.8M
EBITDA
$58.5M
Free Cash Flow
$19.6M
Op Cash Flow
$19.7M
EPS Basic
$-0.46
EPS Diluted
$-1.08
EPS Forward
$-2.71
Gross Margin
116.4%
Op Margin
17.6%
Net Margin
-11.5%
Balance Sheet
Total Assets
$364.4M
Total Liab.
$327.2M
Total Equity
$37.2M
Cash
$311.6M
LT Debt
$12.0M
Book Value/Sh
$1.34
Debt/Equity
0.38x
Current Ratio
9.07
Quick Ratio
9.07
Returns & Growth
ROE
-35.6%
ROA
-3.6%
ROIC
14.6%
Rev Growth YoY
+157.0%
EPS Growth YoY
+91.0%
Price Returns
2W
-10.5%
1M
-15.3%
3M
+51.7%
6M
+100.5%
12M
+275.6%
Technicals
52W High
$69.78
52W Low
$12.93
50d MA
$57.19
200d MA
$36.05
RSI (14)
54.90
ATR (14)
$2.77
Beta
0.41
Avg Volume
588K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$73.88
High
$140.00
Low
$50.00
Median
$63.00
Data updated apr 24, 2026 6:05pm
· Source: financialmodelingprep.com